Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Anesthesiology
Volume 2011 (2011), Article ID 896783, 3 pages
http://dx.doi.org/10.1155/2011/896783
Case Report

Filgrastim as a Rescue Therapy for Persistent Neutropenia in a Case of Dengue Hemorrhagic Fever with Acute Respiratory Distress Syndrome and Myocarditis

Department of Anaesthesiology and Intensive Care, Postgraduate Institute of Medical Education and Research and Dr Ram Manohar Lohia Hospital, New Delhi 10041, India

Received 14 August 2011; Accepted 22 September 2011

Academic Editors: S. Grigoriadis and H. Shankar

Copyright © 2011 Desh Deepak et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. S. Y. Leong, K. T. Wong, T. Y. M. Leong, P. H. Tan, and P. Wannakrairot, “The pathology of dengue hemorrhagic fever,” Seminars in Diagnostic Pathology, vol. 24, no. 4, pp. 227–236, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. H. Y. Lei, T. M. Yeh, H. S. Liu, Y. S. Lin, S. H. Chen, and C. C. Liu, “Immunopathogenesis of dengue virus infection,” Journal of Biomedical Science, vol. 8, no. 5, pp. 377–388, 2001. View at Publisher · View at Google Scholar · View at Scopus
  3. R. G. Wunderink, K. Leeper Jr., R. Schein et al., “Filgrastim in patients with pneumonia and severe sepsis or septic shock,” Chest, vol. 119, no. 2, pp. 523–529, 2001. View at Publisher · View at Google Scholar · View at Scopus
  4. T. J. Smith, J. Khatcheressian, G. H. Lyman et al., “Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline,” Journal of Clinical Oncology, vol. 24, no. 19, pp. 3187–3205, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. A. W. Valley, “New treatment options for managing chemotherapy-induced neutropenia,” American Journal of Health-System Pharmacy, vol. 59, pp. S11–S16, 2002. View at Google Scholar · View at Scopus
  6. Y. B. Saab, L. Sharaf, and I. Zeidan, “Filgrastim use: evaluation in cancer and critically ill non- cancer patients,” Cancer Therapy, vol. 1, pp. 191–196, 2003. View at Google Scholar
  7. S. Nelson, S. M. Belknap, R. W. Carlson et al., “A randomized controlled trial of Filgrastim as an adjunct to antibiotics for treatment of hospitalized patients with community-acquired pneumonia,” Journal of Infectious Diseases, vol. 178, no. 4, pp. 1075–1080, 1998. View at Google Scholar · View at Scopus
  8. K. Bilgin, A. Yaramiş, K. Haspolat, M. A. Taş, S. Günbey, and O. Derman, “A randomized trial of granulocyte-macrophage colony-stimulating factor in neonates with sepsis and neutropenia,” Pediatrics, vol. 107, no. 1, pp. 36–41, 2001. View at Publisher · View at Google Scholar · View at Scopus
  9. A. V. Pisciotta, “Agranulocytosis during antibiotic therapy: drug sensitivity or sepsis?” American Journal of Hematology, vol. 42, no. 1, pp. 132–137, 1993. View at Publisher · View at Google Scholar · View at Scopus